Seagen Inc.

Seattle Genetics, Inc.

Robert Lyon

Svetlana Doronina

Peter Senter

Patrick J Burke

Dennis R Benjamin

Damon L Meyer

Maureen Ryan

Timothy Bovee

John Fay Valliere-Douglass

Christopher Scott Neumann

Kathleen Olivas

Joshua Hunter

Kevin Beam

Bradley Hayes

Kung-Pern Wang

Damon Meyer

John Valliere-Douglass

Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.

Hydrophilic antibody-drug conjugates

Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.

Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.

Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics

The invention is based in part on the observation that a CHO cell oxidizing enzyme, particularly QSOX1, can survive a seemingly rigorous antibody purification process to reduce subsequent conjugation efficiency of the antibody to a drug. Whether the oxidizing enzyme survives the purification procedure depends on which purification techniques are employed which can vary from one antibody to another. With knowledge that contamination with a CHO cell oxidizing enzyme is a potential problem for subsequent conjugation, a suitable purification scheme can be devised for any antibody that eliminates or at least reduces CHO oxidizing enzyme(s) to an acceptable level.

Preparing antibodies from CHO cell cultures for conjugation

The invention provides methods for making antibody conjugates for use in antibody screening assays and antibody conjugates produced by the claimed methods.

Methods for screening antibodies

The present invention provides Ligand-Drug Conjugates, Drug-Linkers, Linkers, and Ligand-Linker Conjugates comprising a self-stabilizing linker assembly component.

Self-stabilizing linker conjugates

Growing community of inventors

Sammamish, WA, United States of America

Robert Lyon